BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 22549727)

  • 1. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
    Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
    Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
    Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
    Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
    Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
    Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p15 Expression Differentiates Nevus from Melanoma.
    Taylor LA; O'Day C; Dentchev T; Hood K; Chu EY; Ridky TW; Seykora JT
    Am J Pathol; 2016 Dec; 186(12):3094-3099. PubMed ID: 27855847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
    Silva JM; Bulman C; McMahon M
    Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.
    Kaplon J; Hömig-Hölzel C; Gao L; Meissl K; Verdegaal EM; van der Burg SH; van Doorn R; Peeper DS
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):640-52. PubMed ID: 24703243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
    Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF
    McNeal AS; Belote RL; Zeng H; Urquijo M; Barker K; Torres R; Curtin M; Shain AH; Andtbacka RH; Holmen S; Lum DH; McCalmont TH; VanBrocklin MW; Grossman D; Wei ML; Lang UE; Judson-Torres RL
    Elife; 2021 Nov; 10():. PubMed ID: 34812139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
    Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
    Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.
    de Keizer PL; Packer LM; Szypowska AA; Riedl-Polderman PE; van den Broek NJ; de Bruin A; Dansen TB; Marais R; Brenkman AB; Burgering BM
    Cancer Res; 2010 Nov; 70(21):8526-36. PubMed ID: 20959475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
    Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
    J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
    Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
    Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAFE600-associated senescence-like cell cycle arrest of human naevi.
    Michaloglou C; Vredeveld LC; Soengas MS; Denoyelle C; Kuilman T; van der Horst CM; Majoor DM; Shay JW; Mooi WJ; Peeper DS
    Nature; 2005 Aug; 436(7051):720-4. PubMed ID: 16079850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.
    Xie X; Koh JY; Price S; White E; Mehnert JM
    Cancer Discov; 2015 Apr; 5(4):410-23. PubMed ID: 25673642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
    Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
    Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic Braf induces melanocyte senescence and melanoma in mice.
    Dhomen N; Reis-Filho JS; da Rocha Dias S; Hayward R; Savage K; Delmas V; Larue L; Pritchard C; Marais R
    Cancer Cell; 2009 Apr; 15(4):294-303. PubMed ID: 19345328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
    Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
    Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
    Cheung M; Sharma A; Madhunapantula SV; Robertson GP
    Cancer Res; 2008 May; 68(9):3429-39. PubMed ID: 18451171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.